Updated on 4 August 2014
"Taiwan's biotech industry is a well carved out miracle. It has now been presented with the opportunity to become second only to the US and a large biotech powerhouse," Mr Den-yih explained to industry leaders.
The event broke its own earlier records by witnessing footfalls of over 10 million. "This is the first time in five years we are able to bring in China-Taiwan Cross-Strait Summit as part of BIO Taiwan events," Dr Johnsee Lee, President, Taiwan BIO and Chairman, Development Center for Biotechnology said during the event.
The highlight of the event was the year's new offering - a roundtable conference on Greater China Bio/Pharma opportunity. The invitation-only roundtable discussion for government officials from both sides, focused on the industry policies, business strategies, partnering models and opportunities on biotech, pharma, diagnostics and biomaterial sectors in China and Taiwan.
The event had 11 countries participating, including West Africa, India, Japan, China, Korea, New Zealand and Australia amongst others. It had companies from France, USA, UK, India, Singapore, Pakistan, Japan and a number of big players from the Chinese mainland.
At a parallel seminar hall, IRPMNA, Taiwan BIO along with delegations from several countries brainstormed about how to leverage MNC's resources for advancing Taiwan's biotech and pharmaceutical industry. Although the public and media did not get to hear pointers from the closed door discussion, the organizers hinted that successful sessions brought out several ideas on how the pie could be make bigger, for both MNCs and local stakeholders.